Clinical experience with exenatide in a routine secondary care diabetes clinic

Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA1c were 114.9 ± 20.6 kg, 10.3 ± 2.1% at initiation; 108.0 ± 15.3 kg (p < 0.0001), 9.0 ± 2.1% (p < 0.001) at 3 months; 109.2 ± 18.2 kg (p < 0.0001), 9.5 ± 2.3% (p = 0.08) at 6 months. Exenatide appears effective in reducing HBA1c and weight.